STADA wins Fundamed Award as Best Generic Company of the Year in Spain
06/21/2019 - 09.25 AM . Press Release
Bad Vilbel, June 21, 2019 – STADA Spain was named the country’s Best Generic Company of the Year at the Fundamed Awards. Fundamed (Foundation Medicines and Healthcare Products) is an organization formed and supported by important companies of the Spanish health sector, prestigious professionals, experts and scientists.
The jury, consisting of more than 30 renowned experts in the field of healthcare in Spain, chose STADA as Best Generic Company of the Year, because of its commitment to the sustainability of the National Health System with the launch of the new pillar of STADA Specialties and the significant role the company played in the supply of Valsartan medicines to Spanish Pharmacies in July 2018.
The award ceremony was held in Madrid on June 18, 2019. Among the guests were representatives of the Spanish government like Faustino Blanco, Secretary General of Health and Consumer Affairs of the Ministry of Health, Ana Pastor, Vice President of the Spanish Parliament, and former Minister of Health Carmen Montón as well as healthcare professionals and representatives of scientific organizations, patient associations and leading pharmaceutical companies.
"For more than 20 years, generic medicines have made a big contribution to the sustainability of the National Health System in Spain, allowing access to pharmacotherapy for millions of patients. I would like to share this award with all the people who have joined during this time and, especially, with all the STADA colleagues worldwide who work for the patients’ health every day with integrity, entrepreneurship, agility and a One STADA mindset”, said Mar Fábregas, General Manager of STADA Spain, who accepted the award on behalf of the company.
About STADA Arzneimittel AG
STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. The company focuses on a two pillar strategy consisting of generics, including specialty pharmaceuticals and non-prescription Consumer Health products. Worldwide, STADA Arzneimittel AG sells its products in approximately 130 countries. In financial year 2018, STADA achieved adjusted Group sales of EUR 2,330.8 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 503.5 million. As of December 31, 2018, STADA employed 10,416 people worldwide.
Additional information for journalists:
STADA Arzneimittel AG / Media Relations / Stadastrasse 2–18 / 61118 Bad Vilbel – Germany / Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-Mail: press(at)stada.de
Or visit us on the Internet at www.stada.com/press
Additional information for capital market participants:
STADA Arzneimittel AG / Investor & Creditor Relations / Stadastrasse 2–18 / 61118 Bad Vilbel – Germany / Phone: +49 (0) 6101 603-4689 / Fax: +49 (0) 6101 603-215 / E-mail: ir(at)stada.de
Or visit us on the Internet at www.stada.com/investor-relations